Gain Therapeutics (NASDAQ:GANX) Receives “Buy” Rating from Roth Mkm

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reissued by stock analysts at Roth Mkm in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $7.00 price target on the stock. Roth Mkm’s target price suggests a potential upside of 336.27% from the company’s current price.

Other analysts have also issued research reports about the company. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research note on Monday, November 25th. Roth Capital raised shares of Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $7.25.

Gain Therapeutics Stock Up 2.2 %

GANX traded up $0.03 on Tuesday, hitting $1.60. 99,210 shares of the company were exchanged, compared to its average volume of 262,513. The company has a market cap of $42.56 million, a PE ratio of -1.46 and a beta of 0.21. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. Gain Therapeutics has a 12 month low of $0.89 and a 12 month high of $5.33. The stock’s fifty day moving average is $2.03 and its 200-day moving average is $1.61.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Warberg Asset Management LLC bought a new stake in Gain Therapeutics during the 2nd quarter worth $66,000. Renaissance Technologies LLC grew its position in shares of Gain Therapeutics by 154.2% in the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after buying an additional 72,000 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after acquiring an additional 88,236 shares during the period. Finally, Hohimer Wealth Management LLC bought a new stake in Gain Therapeutics in the second quarter valued at approximately $422,000. 11.97% of the stock is owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.